Semaglutide for Aging

Overseen By Tiffany M Cortes, MD

Age: 65+

Sex: Any

Trial Phase: Phase 4

Sponsor: The University of Texas Health Science Center at San Antonio

Disqualifiers: Heart disease, Liver disease, Smoke

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

Duration: 20 weeks

20 Participants Needed

Trial Summary

What is the purpose of this trial?

Semaglutide is a medication approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management. This new study will help find out what effects, semaglutide has on people who take the drug and the drug's effect on physical function, body composition, and aging.

Research Team

Tiffany M Cortes, MD

Principal Investigator

UT Health San Antonio

Eligibility Criteria

This trial is for older adults over 65 living on their own, with a BMI of 27 or higher and prediabetes or diabetes. It's not open to smokers or those with heart or liver disease.

Inclusion Criteria

I have prediabetes or diabetes.

I am older than 65.

I live on my own, not in a care facility.

Exclusion Criteria

I have heart disease.

I have liver disease.

You are a smoker.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive semaglutide and lifestyle intervention for 20 weeks

20 weeks

Regular visits with a dietician

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• Lifestyle Counseling
• Semaglutide Injectable Product

Trial Overview The study tests the effects of Semaglutide, an FDA-approved drug for blood sugar control and weight management, along with lifestyle counseling on physical function, body composition, and aging markers in older adults.

Participant Groups

Group I: Semaglutide and lifestyle intervention Experimental Treatment 2 Interventions

Participants will meet with a dietician throughout the study to discuss lifestyle counseling based on recommendation in the diabetes prevention program. They will also be given semaglutide for 20 weeks.

Group II: Lifestyle intervention Active Control 1 Intervention

Participants will meet with a dietician throughout the study to discuss lifestyle counseling based on recommendation in the diabetes prevention program

Who Is Running the Clinical Trial?

The University of Texas Health Science Center at San Antonio

Lead Sponsor

Trials

486

Recruited

92,500+

National Institute on Aging (NIA)

Collaborator

Trials

1,841

Recruited

28,150,000+